Deans' stroke musings: Blood Biomarkers for Detecting Brain Injury in COVID-19 Patients

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, November 17, 2020

Blood Biomarkers for Detecting Brain Injury in COVID-19 Patients

Detecting brain injury after the fact is way too late. We need protocols that prevent such injury. Which is why I'm insisting on heparin immediately.

Blood Biomarkers for Detecting Brain Injury in COVID-19 Patients

-COVID-19 can directly cause neurologic symptoms and long-term neurological disease. Elevations of blood biomarkers indicative of brain injury have been reported in the blood and cerebrospinal fluid of COVID-19 patients. Clinical application of blood biomarkers to improve medical management of COVID-19 patients is reported in the peer-reviewed Journal of Neurotrauma. Click here to read the article now.

“The COVID-19 pandemic poses significant risks for acute and persistent neurological deficits, as well as possible increased risk for neurodegenerative diseases,” state Ronald Hayes, PhD, Banyan Biomarkers, and coauthors. “The use of blood biomarkers of brain injury integrated with additional existing diagnostic tools with big dataset analytics could provide timely, cost effective approaches to address this increasingly urgent unmet medical need.”

“Although presented in the context of a review article, the manuscript represents so much more,” says John Povlishock, PhD, Editor-in-Chief of Journal of Neurotrauma. “The paper concisely reviews the increased risks of the COVID-19 patient for persistent neurological deficits, psychiatric disorders, and potential neurodegenerative diseases, while describing mechanisms of the CNS penetrance and action of the virus. The paper provides not only an assessment of the challenges presented by the effects of COVID-19 on the brain, but also provides specific recommendations to address them. In all, this review masterfully argues that many of the technologies needed to probe the effects of the COVID-19 virus on the brain are in hand and can be rapidly applied.”

About the Journal

Journal of Neurotrauma is an authoritative peer-reviewed journal published 24 times per year in print and online that focuses on the latest advances in the clinical and laboratory investigation of traumatic brain and spinal cord injury. Emphasis is on the basic pathobiology of injury to the nervous system, and the papers and reviews evaluate preclinical and clinical trials targeted at improving the early management and long-term care and recovery of patients with traumatic brain injury. Journal of Neurotrauma is the official journal of the National Neurotrauma Society and the International Neurotrauma Society. Complete tables of content and a sample issue may be viewed on the Journal of Neurotrauma website.

About the Publisher

Mary Ann Liebert, Inc., publishers is known for establishing authoritative peer-reviewed journals in promising areas of science and biomedical research. A complete list of the firm’s 90 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

/Public Release. The material in this public release comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.